Abstract 12805: Impact of Lipoprotein (a) as Residual Risk on Long-term Outcomes in Patients Underwent PCI
Background: Previous clinical trials have shown that LDL-C reduction with statin significantly reduced cardiovascular events. However, residual cardiovascular risk remained despite the achievement of target lipid profile. The serum lipoprotein (a) [Lp(a)] level is independent risk factors for cardiovascular disease (CVD). However, clinical implication of Lp(a) in patients who were achieving target lipid profile is uncertain. We sought to assess the role of Lp(a) as residual risk in male patients underwent percutaneous coronary intervention (PCI).
Methods: During the observation period (1997 to 2011), total 3508 patients were performed in PCI. Of these patients, 330 consecutive patients were achieved on target lipid profile (LDL-C≤100mg/dl and HDL-C≧40mg/dl, TG≤150mg/dl). These patients were included and analyzed. Then, patients were divided into 2 groups according to Lp(a) baseline level: high Lp(a) group (≧30mg/dl, n=95) and low group (≤30mg/dl, n=235). Primary end point was all cause death and ACS.
Results: Mean follow-up period was 4.7 years. There was no significant difference the clinical baseline characteristics between 2 groups. The incidence of all cause death and ACS was significantly higher in the high Lp(a) group than in the low Lp(a) group (28.4% vs 14.5%, P≤0.01). Multivariate analysis showed that high Lp(a) was an independent predictor of major adverse events (HR 2.47, CI 1.19-5.06, p=0.02).
Conclusions: Lp(a) levels could predict the prognosis of the patients who achieved the targeted value of the lipid treatment.
- © 2013 by American Heart Association, Inc.